- Home
- BMRC vs CTNM Comparison
BMRC vs CTNM Comparison
Compare BMRC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BMRC | CTNM |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.3M | 489.4M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BMRC | CTNM |
|---|---|---|
| Price | $25.13 | $12.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.67 | $19.00 |
| AVG Volume (30 Days) | 69.1K | ★ 134.3K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $391.81 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $48.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.21 | $3.57 |
| 52 Week High | $28.48 | $16.33 |
Technical Indicators
Market Signals| Indicator | BMRC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 41.54 |
| Support Level | $24.80 | $12.43 |
| Resistance Level | $27.03 | $13.26 |
| Average True Range (ATR) | 0.64 | 0.71 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 9.39 | 11.66 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.